PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation

1. J. K. Slack-Davis, K. H. Martin, R. W. Tilghman, M. Iwanicki, E. J. Ung, C. Autry, M. J. Luzzio, B. Cooper, J. C. Kath, W. G. Roberts and J. T. Parsons, Cellular characterization of a novel focal adhesion kinase inhibitor, J. Biol. Chem. 282 (2007) 14845-14852; DOI: 10.1074/jbc.M606695200.10.1074/jbc.M606695200Search in Google Scholar

2. M. J. van Nimwegen and B. van der Water, Focal adhesion kinase: A potential target in cancer therapy, Biochem. Pharmacol. 73 (2007) 597-609; DOI: 10.1016/j.bcp.2006.08.011.10.1016/j.bcp.2006.08.011Search in Google Scholar

3. J. D. Hood and D. A. Cheresh, Role of integrins in cell invasion and migration, Nat. Rev. Cancer 2 (2002) 91-100; DOI: 10.1038/nrc727.10.1038/nrc727Search in Google Scholar

4. T. Miyazaki, H. Kato, M. Nakajima, M. Sohda, Y. Fukai, N. Masuda, R. Manda, M. Fukuchi, K. Tsukada and H. Kuwano, FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma, Br. J. Cancer 89 (2003) 140-145; DOI: 10.1038/sj.bjc.6601050.10.1038/sj.bjc.6601050Search in Google Scholar

5. J. T. Parsons, J. Slack-Davis, R. Tilghman and W. G. Roberts, Focal adhesion kinase: Targeting adhesion signaling pathways for therapeutic intervention, Clin. Cancer Res. 14 (2008) 627-632; DOI: 10.1158/1078-0432.CCR-07-2220.10.1158/1078-0432.CCR-07-2220Search in Google Scholar

6. J. M. Stiles, R. K. Rowntree, C. Amaya, D. Diaz, V. Kokta, D. C. Mitchell and A. B. Brad, Gene expression analysis reveals marked differences in the transcriptome of infantile hemangioma endothelial cells compared to normal dermal microvascular endothelial cells, Vasc. Cell 5 (2013) 1-12; DOI: 10.1186/2045-824X-5-6.10.1186/2045-824X-5-6Search in Google Scholar

7. L. V. Owens, L. Xu, G. A. Dent, X. Yang, G. C. Sturge, R. J. Craven and W. G. Cance, Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer, Ann. Surg. Oncol. 3 (1996) 100-105; DOI: 10.1007/BF02409059.10.1007/BF02409059Search in Google Scholar

8. D. D. Schlaepfer, C. R. Hauck and D. J. Sieg, Signaling through focal adhesion kinase, Prog. Biophys. Mol. Biol. 71 (1999) 435-478; DOI: 10.1016/S0079-6107(98)00052-2.10.1016/S0079-6107(98)00052-2Search in Google Scholar

9. L. A. Cohen and J. L. Guan, Mechanisms of focal adhesion kinase regulation, Curr. Cancer Drug Tar. 5 (2005) 629-643; DOI: 10.2174/156800905774932798.10.2174/15680090577493279816375667Search in Google Scholar

10. P. Mabeta and M. S. Pepper, Inhibition of hemangioma development in a syngeneic mouse model correlates with Bcl-2 suppression and the inhibition of Akt kinase activity, Angiogenesis 15 (2012) 131-139; DOI: 10.10007/s10456-011-9248-7.Search in Google Scholar

11. H. P. Gerber, A. McMurtrey, J. Kowalski, M. Yan, B. A. Keyt, V. Dixit and N. Ferrara, Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation, J. Biol. Chem. 273 (1998) 30336-30343; DOI: 10.1074/jbc.273.46.30336.10.1074/jbc.273.46.303369804796Search in Google Scholar

12. K. T. Sabapathy, M. S. Pepper, F. Kiefer, U. Möhle-Steinlein, F. Tacchini-Cottier, I. Fetka, G. Breier, W. Risau, P. Carmeliet, R. Montesano and E. F.Wagner, Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system, J. Cell Biol. 137 (1997) 953-963; DOI: 10.1083/jcb.137.4.953.10.1083/jcb.137.4.95321398399151696Search in Google Scholar

13. P. Mabeta and M. S. Pepper, Altered expression of platelet factor 4 and basic fibroblast growth factor correlates with the inhibition of tumor growth in mice, Biomed. Pharmacol. 69 (2015) 186-190; DOI: 10.1016/j.biopha.2014.11.018.10.1016/j.biopha.2014.11.01825661356Search in Google Scholar

14. M. A. Cabrita, L. M. Jones, J. L. Quizi, L. A. Sabourin, B. C. McKay and C. L. Addison, Focal adhesion kinase inhibitors are potent anti-angiogenic agents, Mol. Oncol. 5 (2011) 517-526; DOI: 10.1016/ jmolonc.2011.10.004.10.1016/j.molonc.2011.10.004552832022075057Search in Google Scholar

15. S. Hiscox, P. Barnfather, E. Hayes, P. Bramble, J. Christensen, R. I. Nicholson and P. Barrett-Lee, Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells, Breast Cancer Res. Treat. 125 (2011) 659-669; DOI: 10.1007/s10549-010-0857-4.10.1007/s10549-010-0857-420354780Search in Google Scholar

16. P. W. Bryant, Q. Zheng and K. M. Pumiglia, Focal adhesion kinase is a phospho-regulated repressor of Rac and proliferation in human endothelial cells, Biol. Open 15 (2012) 723-730; DOI: 10.1242/ bio.20121008.10.1242/bio.20121008350722523213465Search in Google Scholar

17. L. Portt, G. Norman, C. Clapp, M. Greenwood and M. T. Greenwood, Anti-apoptosis and cell survival: A review, Biochim. Biophys. Acta 1813 (2011) 238-259; DOI: 10.1016/j.bbamcr.2010.10.010.10.1016/j.bbamcr.2010.10.01020969895Search in Google Scholar

18. X. Zhao and J. L. Guan, Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis, Adv. Drug Deliver. Rev. 63 (2011) 610-615; DOI: 10.1016/j.addr.2010.11.001.10.1016/j.addr.2010.11.001313282921118706Search in Google Scholar

19. S. K. Mitra, D. A. Hanson and D. D. Schlaepfer. Focal adhesion kinase: in command and control of cell motility, Nat. Rev. Mol. Cell Biol. 6 (2005) 56-68; DOI: 10.1038/nrm1549.10.1038/nrm154915688067Search in Google Scholar

20. B. Tavora, S. Batista, L. Reynolds, S. Jadeja, S. Robinson, V. Kostourou, I. Hart, M. Fruttiger, M. Parsons and K. M. Hodivala-Dilke, Endothelial FAK is required for tumour angiogenesis, EMBO Mol. Med. 2 (2010) 516-528; DOI: 10.1002/emmm.201000106.10.1002/emmm.201000106337734421154724Search in Google Scholar

21. L. H. Xu, X. Yang, C. A. Bradham, D. A. Brenner, J. A. S. Baldwin, R. J. Craven and W. G. Cance, The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells, J. Biol. Chem. 275 (2000) 30597-30604; DOI: 10.1074/jbc. M910027199. 10.1074/jbcSearch in Google Scholar

22. C. Wiza, E. B. M. Nascimento and D. M. Ouwens, Role of PRAS40 in Akt and mTOR signaling in health and disease, Am. J. Physiol. Endocrinol. Metab. 302 (2012) E1453-E1460; DOI: 10.1152/ajpendo.00660.2011.10.1152/ajpendo.00660.201122354785Search in Google Scholar

23. H. Wang, Q. Zhang, Q. Wen, Y. Zheng, L. Philip, H. Jiang, J. Lin and W. Zheng, Proline-rich Akt substrate of 40 kDa (PRAS40): A novel downstream target of P13k/Akt signaling pathway, Cell Signal. 24 (2012) 17-24; DOI: 10.1016/j.cellsig.2011.08.010.10.1016/j.cellsig.2011.08.01021906675Search in Google Scholar

24. I. Ruvinsky, N. Sharon, T. Lerer, H. Cohen, M. Stolovich-Rain, T. Nir, Y. Dor, P. Zisman and O. Meyuhas, Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis, Genes Dev. 19 (2005) 2199-2211; DOI: 10.1101/gad.351605.10.1101/gad.351605122189016166381Search in Google Scholar

25. B. Gan, Y. Yoo and J. Guan, Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of S6 kinase activation and cell growth, J. Biol. Chem. 281 (2006) 37321-37329; DOI: 10.1074/jbc.M605241200.10.1074/jbc.M60524120017043358Search in Google Scholar

26. A. Porras and C. Guerrero, Role of p38α in apoptosis: Implication in cancer development and therapy, Atlas Genet. Cytogenet. Oncol. Haematol. 15 (2011) 316-326; DOI: 10.4267/2042/44993.10.4267/2042/44993Search in Google Scholar